Not every BP medicine is heart-friendly
Educate patients taking GLP-1 receptor agonists who have risk factors for developing NAION about the importance of presenting to their eyecare provider immediately should they experience any painless monocular vision loss
Below 1 mg is supported by acute Phase 1 readings in lean Asian participants and real-world reports, but not by a chronic dosing trial
1 mg dose: GI event rates only modestly above placebo stomach pain is uncommon at this level 4 mg (escalated from 1 mg): 60% GI events stomach pain begins to appear but is generally mild 4 mg (single dose, no escalation): 63.6% GI events higher than the escalated group, confirming that jumping to a dose causes more stomach pain than titrating up 8 mg (escalated): 57.5% GI events notably, lower than the 4 mg single-dose group because the body has adapted through gradual increases 12 mg (escalated): 66.7% GI events the highest rate, but most events were Grade 1-2 (mild to moderate) and transient The critical takeaway: gradual dose titration is the single most effective strategy for reducing stomach pain on retatrutide
Dardano A, Bianchi C, Garofolo M, Del Prato S
In line with practice for similar agents, a washout period before planned pregnancy should be discussed with a healthcare professional Patients experiencing severe or persistent abdominal pain, signs of an allergic reaction, or significant changes in heart rate should seek prompt medical advice
